dpp-4 inhibitor and glp-1 receptor agonist combination not recommended guideline What's next after metformin for diabetes? Role of DPP-4 Inhibitors in

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D

other outcomes were cardiovascular and total death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure (HHF), and renal outcome

Adipogen Life Sciences

Background: Type 2 diabetes mellitus (T2D) is associated with an increased fracture risk

It has been studied in human clinical trials and shown to support metabolic balance, healthy blood glucose regulation, inflammation management, and improved insulin function

The aim of this narrative review is to critically assess the renoprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in managing albuminuria among patients with type 2 diabetes mellitus within the framework of personalized ...